Defense Health Agency Contracting Activity - DHACA
· Federal agency
Spinal Cord Injury Research Program Clinical Trial Award - Rehabilitation
The Clinical Trial Award – Rehabilitation (CTA-R) supports rapid implementation of clinical trials with the potential to have a significant impact on the understanding of SCI and amelioration of its consequences. All stu...
64
match
Award$0Deadline6036 days agoLocationAlabamaTypegrantLevelFederalClosedposted Jul 13, 2009
✦ AI Summary
Who can apply: Federal-level applicants (see eligibility for details).
Funding amount: total funding pool ~$9,600,000.
Next deadline: December 10, 2009.
Issued by: Defense Health Agency Contracting Activity - DHACA.
The “key facts” mode pulls structured fields directly from the official source posting (amount, deadline, eligibility tags). The AI mode adds a short plain-English narrative on top, generated from the same source. Always verify with the agency before applying.
AI-generated. Always verify with the official source.
Award amount
$0
Deadline
6036 days ago
Dec 10, 2009
Total pool
$9.6M
About this opportunity
The Clinical Trial Award – Rehabilitation (CTA-R) supports rapid implementation of clinical trials with the potential to have a significant impact on the understanding of SCI and amelioration of its consequences. All studies must be focused on rehabilitative aspects of SCI. All studies must also be applicable to the health care needs of the military service members, their family members, and/or the veteran population. Funding from this award mechanism cannot be used for preclinical research studies. Principal Investigators (PIs) seeking funding for a preclinical research project should utilize one of the other applicable FY09 SCIRP award mechanisms (for more information about those mechanisms, see http://cdmrp.army.mil). PIs must clearly specify in the Clinical Protocol (main body of the application) which type of clinical trial is being proposed: Phase 0, Phase I, Phase II, Phase III or a combination. For descriptions of each type of clinical trial, please refer to http://www.clinicaltrials.gov and http://www.fda.gov/cder/guidance/6384dft.htm. In addition, refer to the Application Instructions & General Information, Appendix 6, for helpful information about distinguishing clinical trials and clinical research. The proposed clinical trial is expected to begin within 12 months of the award date. CTA-R applications should: Demonstrate availability of, and access to, a suitable patient population that will support a meaningful outcome for the study. Describe clearly defined, focused endpoints for the proposed clinical trial that correspond to the design and sample size proposed. DOD Spinal Cord Injury Clinical Trial Award 4 Clearly articulate the statistical analyses plan. Include a power analysis reflecting sample size projections that will clearly answer the objectives of the study. Discuss the potential impact of the study results for patients with the specified disease/condition. Include a study coordinator who will guide the clinical protocol through Institutional Review Board (IRB), Human Subjects Research Review Board (HSRRB), and other regulatory approval processes; coordinate activities from all sites participating in the trial, and coordinate participant accrual. The clinical trial should have a potentially high impact. The focus must be clearly on SCI rehabilitation. Investigational New Drug (IND) approvals, if applicable, should be initiated or completed before submission to the CTA-R mechanism. If IND/IDE (investigational device exemption) approval is not received by June 30, 2010, the Government reserves the right to revoke funding. Demonstrate institutional support. Multi-institutional Clinical Trials: If the proposed clinical trial is multi-institutional, plans for communication and data transfer between the collaborating institutions, as well as how specimens and/or imaging products obtained during the study will be handled, should be included in the appropriate sections of the Clinical Protocol. A separate intellectual and material property plan agreed upon by all participating institutions is also required for multi-institutional clinical trials. Use of Human Subjects and Human Biological Substances: All Department of Defense (DOD)-funded research involving human subjects and human biological substances must be reviewed and approved by the USAMRMC Office of Research Protections (ORP), Human Research Protection Office (HRPO), in addition to local IRBs. The HRPO is mandated to comply with specific laws and directives governing all research involving human subjects that is conducted or supported by the DOD. These laws and directives are rigorous and detailed, and will require information in addition to that supplied to the local review board. Allow a minimum of 6 months for regulatory review and approval processes for studies involving human subjects. Refer to Application Instructions & General Information, Appendix 6, for detailed information.
Read the agency's eligibility checklist before you start — it's almost always shorter than the full NOFO and will tell you in 90 seconds whether to keep going.
Need help getting in touch with the right agency contact?
Create a free account and our specialists will guide you through the application end-to-end.